10 September 2018
A new report by visiongain forecasts that the global pharma contract sales market will generate $7.36 billion in 2020. That revenue prediction and others appear in Pharma Contract Sales Market 2016-2026: Revenue Forecasts for Outsourced Detailing, Including Teledetailing and eDetailing, as well as Medical Education and Sample Management Services. That study gains publication in March 2016. Visiongain is a business information publisher and consultancy in London, UK.
Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said:
“The pharmaceutical contract sales market consists of revenues achieved by CSOs (contract sales organisations), which assist other companies in the sales and marketing of products and services. Outsourcing medical sales offers many benefits to pharmaceutical companies, and contract sales is one of the fastest growing sectors of the overall pharmaceutical outsourcing market, driven by a range of factors including new technologies, sales models and drug launches. However, the market faces many challenges, including the declining access to doctors, patent expiries for leading products, and large companies choosing to retain sales activities in-house.”
Visiongain’s updated analysis provides multilevel revenue forecasts for the pharma contract sales market from 2016 to 2026.
First it shows revenue predictions to 2026 for seven submarkets:
• Contract detailing (personal promotion/field sales)
• Contract non-personal promotion, with further sub-forecasting for teledetailing, eDetailing and other selling operations
• Medical education services
• Sample management services.
In addition, there appear four revenue forecasts to 2026 for prominent therapeutic segments of the overall pharma contract sales market:
• Cardiovascular diseases
• Metabolic disorders
• Cancer treatments
• Other drugs (grouped prediction).
That investigation also shows revenue forecasts to 2026 for 11 national markets:
• Germany, UK, France, Italy and Spain
• China, India, Brazil and Russia.
Companies that new study assesses include Quintiles, inVentiv Health, UDG Healthcare and Publicis Touchpoint Solutions. Interviews with three organisations – OnCall, Apodi and Hilver – also appear.
Visiongain’s new report discusses forces stimulating revenue expansion over the next ten years, as well as forces restraining the CSO industry. Pharma Contract Sales Market 2016-2026 adds to visiongain’s analytical reports on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices. Their purpose is to help organisations assess the potentials of industries and markets.
The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.
18 January 2021
Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.
08 January 2021
The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.
07 January 2021
Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.